Integra Lifesciences Holdings Corp (IART)
22.88
-0.39
(-1.68%)
USD |
NASDAQ |
Nov 15, 16:00
22.86
-0.02
(-0.07%)
After-Hours: 20:00
Integra Lifesciences Holdings Research and Development Expense (TTM): 108.45M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 108.45M |
| June 30, 2024 | 107.61M |
| March 31, 2024 | 104.43M |
| December 31, 2023 | 104.19M |
| September 30, 2023 | 106.69M |
| June 30, 2023 | 104.83M |
| March 31, 2023 | 103.83M |
| December 31, 2022 | 101.19M |
| September 30, 2022 | 99.14M |
| June 30, 2022 | 100.23M |
| March 31, 2022 | 94.76M |
| December 31, 2021 | 93.05M |
| September 30, 2021 | 90.50M |
| June 30, 2021 | 84.13M |
| March 31, 2021 | 78.94M |
| December 31, 2020 | 77.38M |
| September 30, 2020 | 79.82M |
| June 30, 2020 | 79.36M |
| March 31, 2020 | 82.07M |
| December 31, 2019 | 79.57M |
| September 30, 2019 | 75.26M |
| June 30, 2019 | 76.56M |
| March 31, 2019 | 78.04M |
| December 31, 2018 | 78.04M |
| September 30, 2018 | 74.92M |
| Date | Value |
|---|---|
| June 30, 2018 | 69.65M |
| March 31, 2018 | 66.29M |
| December 31, 2017 | 63.46M |
| September 30, 2017 | 60.18M |
| June 30, 2017 | 60.27M |
| March 31, 2017 | 59.20M |
| December 31, 2016 | 58.16M |
| September 30, 2016 | 58.12M |
| June 30, 2016 | 56.93M |
| March 31, 2016 | 54.27M |
| December 31, 2015 | 50.90M |
| September 30, 2015 | 47.04M |
| June 30, 2015 | 44.24M |
| March 31, 2015 | 45.97M |
| December 31, 2014 | 47.46M |
| September 30, 2014 | 42.49M |
| June 30, 2014 | 44.41M |
| March 31, 2014 | 42.47M |
| December 31, 2013 | 42.62M |
| September 30, 2013 | 50.44M |
| June 30, 2013 | 50.49M |
| March 31, 2013 | 51.82M |
| December 31, 2012 | 51.01M |
| September 30, 2012 | 51.55M |
| June 30, 2012 | 51.63M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
77.38M
Minimum
Dec 2020
108.45M
Maximum
Sep 2024
94.01M
Average
96.95M
Median
Research and Development Expense (TTM) Benchmarks
| Boston Scientific Corp | 1.519B |
| Haemonetics Corp | 60.10M |
| ResMed Inc | 311.34M |
| Globus Medical Inc | 182.60M |
| Perspective Therapeutics Inc | 28.53M |